{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:51:19Z","timestamp":1777942279488,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To assess the efficacy, safety, and clinical application of tretinoin 0.1%-benzoyl peroxide 3% cream for the topical treatment of acne vulgaris.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A systematic review of the literature was performed using the terms Twyneo OR tretinoin and benzoyl peroxide OR S6G5T-3 in MEDLINE (PubMed) and EMBASE. ClinicalTrials.gov was searched to obtain completed clinical trial results not published elsewhere.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All human studies published in English prior to November 2022 related to pharmacology, clinical trials, safety, and efficacy were evaluated for inclusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>In two 12-week, phase 3, randomized, vehicle-controlled clinical trials, tretinoin 0.1%-benzoyl peroxide 3% cream significantly reduced inflammatory and noninflammatory facial acne lesions and significantly improved Investigator Global Assessment (IGA) rating to clear or almost clear. The cream has a suitable safety profile, with application site pain and dryness as the most common adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison to Existing Agents:<\/jats:title>\n                    <jats:p>Tretinoin-BPO had similar IGA success compared to other topical retinoid and retinoid-BPO treatments for acne vulgaris. Compared to individual tretinoin and benzoyl peroxide therapy, the combination product streamlines application, which will improve medication adherence; however, the cost of tretinoin-BPO cream may be prohibitive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Tretinoin 0.1%-benzoyl peroxide 3% cream is safe and effective for the treatment of moderate-to-severe acne. Long-term trial data on efficacy and tolerability are not yet available.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221147338","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:56:55Z","timestamp":1673657815000},"page":"1088-1093","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Tretinoin 0.1% and Benzoyl Peroxide 3% Cream for the Treatment of Facial Acne Vulgaris"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0715-9204","authenticated-orcid":false,"given":"Christina","family":"Kontzias","sequence":"first","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mallory","family":"Zaino","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA"},{"name":"Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA"},{"name":"Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"bibr1-10600280221147338","unstructured":"Sutaria AH, Masood S, Schlessinger J. Acne Vulgaris. StatPearls Publishing. Accessed September 1, 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459173\/"},{"key":"bibr2-10600280221147338","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0185-2"},{"key":"bibr3-10600280221147338","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12149"},{"key":"bibr4-10600280221147338","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0490B"},{"key":"bibr5-10600280221147338","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037"},{"key":"bibr6-10600280221147338","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519847367"},{"key":"bibr7-10600280221147338","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S268499"},{"key":"bibr8-10600280221147338","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcis.2020.06.114"},{"key":"bibr9-10600280221147338","unstructured":"Sol-Gel Technologies. Sol-Gel Technologies announces FDA approval of TWYNEO. Published July 17, 2021. Accessed September 1, 2022. https:\/\/ir.sol-gel.com\/news-releases\/news-release-details\/sol-gel-technologies-announces-fda-approval-twyneor"},{"key":"bibr10-10600280221147338","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.17633"},{"issue":"7","key":"bibr11-10600280221147338","first-page":"657","volume":"8","author":"Fakhouri T","year":"2009","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"bibr12-10600280221147338","first-page":"26","volume":"3","author":"Del Rosso JQ","year":"2010","journal-title":"J Clin Aesthet Dermatol"},{"key":"bibr13-10600280221147338","unstructured":"Twyneo (tretinoin and benzoyl peroxide) [package insert]. Zug, Switzerland: Galderma; 2021."},{"key":"bibr14-10600280221147338","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(83)70209-4"},{"key":"bibr15-10600280221147338","unstructured":"US National Library of Medicine. A study of S6G5T-3 in the treatment of acne vulgaris. ClinicalTrials.gov identifier: NCT03761784. Date unknown. Updated December 16, 2021. Accessed September 1, 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03761784?cond=S6G5T3+in+the+Treatment+of+Acne+Vulgaris&draw=2&rank=1"},{"key":"bibr16-10600280221147338","unstructured":"US National Library of Medicine. A study of S6G5T3 in the treatment of acne vulgaris. ClinicalTrials.gov identifier: NCT03761810. Date unknown. Updated December 16, 2021. Accessed September 1, 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT03761810"},{"key":"bibr17-10600280221147338","unstructured":"Food and Drug Administration. NDA 214902 multi-disciplinary review and evaluation. Published October 18, 2018. Accessed November 18, 2022. https:\/\/www.fda.gov\/media\/151645\/download"},{"key":"bibr18-10600280221147338","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.10.879"},{"key":"bibr19-10600280221147338","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2022.4275"},{"key":"bibr20-10600280221147338","unstructured":"Drugs.com. Twyneo price, coupons, copay, and patient assistance programs. Date unknown. Accessed September 25, 2022. https:\/\/www.drugs.com\/price-guide\/twyneo"},{"key":"bibr21-10600280221147338","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020934892"},{"key":"bibr22-10600280221147338","unstructured":"TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%\/3%. Savings & support. Date unknown. Accessed September 25, 2022. https:\/\/www.twyneo.com\/savings-support\/?gclid=EAIaIQobChMIrO6Ogp2w-gIVYRpMCh1XeQtjEAAYASABEgJNufD_BwE&gclsrc=aw.ds"},{"key":"bibr23-10600280221147338","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1181256"},{"issue":"5","key":"bibr24-10600280221147338","first-page":"27","volume":"4","author":"Kircik LH","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"bibr25-10600280221147338","unstructured":"GoodRx. Tretinoin. Date unknown. Updated November 18, 2022. Accessed November 18, 2022. https:\/\/www.goodrx.com\/tretinoin?form=tube-of-cream&dosage=20g-of-0.1%25&quantity=1&label_override=tretinoin"},{"key":"bibr26-10600280221147338","unstructured":"GoodRx. Benzoyl peroxide. Date unknown. Updated November 18, 2022. Accessed November 18, 2022. https:\/\/www.goodrx.com\/benzoyl-peroxide?form=tube-of-gel&dosage=60g-of-10%25&quantity=1&label_override=benzoyl-peroxide"},{"key":"bibr27-10600280221147338","doi-asserted-by":"publisher","DOI":"10.1177\/1932296819832653"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221147338","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221147338","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221147338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:00Z","timestamp":1777374780000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221147338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1177\/10600280221147338"],"URL":"https:\/\/doi.org\/10.1177\/10600280221147338","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}